StemRIM narrows interim loss as it ramps R&D on regenerative drug pipeline

The latest announcement is out from StemRIM Inc. ( (JP:4599) ).

StemRIM reported no operating revenue and a net loss of ¥928 million for the six months to Jan. 31, 2026, narrowing slightly from the previous year’s ¥1,048 million loss as basic loss per share improved to ¥14.91. Total assets fell to ¥6,812 million and the equity ratio declined to 74.6%, while the company again declared no interim dividend and has withheld a full-year earnings forecast due to the volatility of milestone income.

Management said it will continue advancing its flagship Regeneration-Inducing Medicine candidate Redasemtide and subsequent pipeline assets toward clinical development and out-licensing, with forecast cash R&D spending of ¥1.3–1.7 billion and SG&A of ¥230–310 million in the current fiscal year. StemRIM noted potential upfront and milestone payments from new and existing partnerships but emphasized it has already secured sufficient funding to support its research and development activities through 2028, offering some visibility for investors despite ongoing losses and uncertain revenue timing.

The most recent analyst rating on (JP:4599) stock is a Hold with a Yen280.00 price target. To see the full list of analyst forecasts on StemRIM Inc. stock, see the JP:4599 Stock Forecast page.

More about StemRIM Inc.

StemRIM Inc., listed on the Tokyo Stock Exchange, is a Japanese biotechnology company focused on developing Regeneration-Inducing Medicine, led by its peptide drug candidate Redasemtide created from HMGB1. The company’s business model is heavily reliant on R&D and milestone and licensing revenues from pharmaceutical partners, making its earnings highly sensitive to partner development strategies and timelines.

Average Trading Volume: 188,864

Technical Sentiment Signal: Sell

Current Market Cap: Yen18.8B

For detailed information about 4599 stock, go to TipRanks’ Stock Analysis page.